Therapies targeting PD-1 and CTLA-4 have drastically improved the outcomes in cancers like melanoma and lung cancer, while the advent of CAR-T cell therapy has demonstrated exceptional success in treating blood cancers, particularly in relapsed or refractory acute lymphoblastic leukemia and large B-cell lymphoma [6]. This evidence concerns the gene CTLA4 and melanoma.